Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTICLATE CAP vs AMZEEQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.
Topical antibiotic and anti-inflammatory: inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and reduces pro-inflammatory cytokine production.
Treatment of infections caused by susceptible bacteria, including respiratory tract infections, urinary tract infections, and acne vulgaris
FDA-approved for the treatment of inflammatory lesions of rosacea
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
Apply a thin layer to affected areas twice daily (morning and evening). Topical, 1.5% w/w.
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal half-life is approximately 28 days due to accumulation in the skin and hair follicles; clinical context: supports once-weekly dosing.
Primarily hepatic; metabolites include 4-epimino derivatives; not significantly metabolized via CYP450.
Minimal systemic absorption; not extensively metabolized.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal: 30% as unchanged drug; Fecal: 70% as metabolites and unchanged drug via biliary excretion.
90-95% bound to serum proteins, primarily albumin
99% bound to plasma proteins, primarily albumin and lipoproteins.
0.75 L/kg (50-70 L in adults); distributes well into tissues including bone, teeth, and synovial fluid
Approximately 12 L/kg, indicating extensive distribution into tissues including skin and sebaceous glands.
Oral: 90-100% (capsule); food or dairy reduces absorption by up to 50%
Topical: Minimal systemic absorption, approximately 1% of applied dose.
e GFR 30-59 m L/min: 350 mg once daily; e GFR <30 m L/min: not recommended.
No dosage adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B or C: 175 mg once daily.
No dosage adjustment required for hepatic impairment.
Not established for children <12 years; for ≥12 years, same as adult dosing.
Not recommended for patients under 12 years of age; safety and efficacy not established.
Initiate at 175 mg once daily; titrate cautiously based on renal function.
No specific dose adjustment; use same as adults with caution for skin fragility.
Photosensitivity: severe sunburn can occur with sun exposure; discontinue if photosensitivity occurs. Tooth development: use during tooth development (last half of pregnancy, infancy, childhood to age 8) may cause permanent tooth discoloration. Bone growth: may retard bone growth in premature infants. Renal toxicity: may cause azotemia, hyperphosphatemia, and acidosis. Avoid in renal impairment.
No black box warning.
Photosensitivity, tooth discoloration, bone growth retardation, renal impairment, hepatotoxicity, increased intracranial pressure, superinfection, and use in pregnancy/lactation.
Use may result in overgrowth of nonsusceptible organisms including fungi.,Avoid contact with eyes, mouth, and mucous membranes.,Not for oral, ophthalmic, or intravaginal use.
Hypersensitivity to tetracyclines, pregnancy, breastfeeding, children under 8 years, renal impairment, and concurrent use with oral retinoids.
Hypersensitivity to any component of the formulation.
Avoid food and beverages for at least 1 hour before and after administration, as they can reduce the efficacy of activated charcoal. Do not mix with milk or ice cream, as they decrease binding capacity. Administer with water or a non-carbonated, non-alcoholic drink.
No significant food interactions reported with topical AMZEEQ. However, oral minocycline absorption is affected by dairy products; for topical foam, no dietary restrictions are necessary.
First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known to cause permanent tooth discoloration (enamel hypoplasia) and reversible inhibition of bone growth; use contraindicated after 15 weeks gestation.
Limited human data; animal studies show no teratogenic effects at systemic exposures up to 1.7 times the MRHD. No known fetal risk; avoid first trimester due to theoretical risk from systemic absorption.
Tetracyclines are excreted in breast milk but absorption by the infant is limited due to chelation with milk calcium; M/P ratio for doxycycline is approximately 0.3-0.4. Theoretical risk of tooth staining and bone inhibition, but clinical significance is low with short-term use; caution with prolonged therapy.
Unknown if excreted in human milk; M/P ratio not available. Use with caution; avoid application to breast area.
No dosage adjustment is typically recommended for doxycycline in pregnancy due to minimal pharmacokinetic changes; however, use is generally avoided in the second and third trimesters. If indicated, standard dosing may be used in the first trimester with caution.
No dosage adjustment required; pharmacokinetics in pregnancy not studied.
ACTICLATE CAP is a high-dose activated charcoal formulation used for acute poisoning or overdose. Administer within 1 hour of ingestion for optimal efficacy. Do not use in patients with impaired consciousness unless the airway is protected. Monitor for vomiting and ensure rapid administration via nasogastric tube if necessary. Not effective for alcohols, metals, or caustics.
AMZEEQ (minocycline) 4% foam is a topical antibiotic indicated for inflammatory lesions of rosacea. Avoid contact with eyes and mucous membranes. Use once daily. May cause skin yellowing (pseudolacte) and hyperpigmentation, especially in dark-skinned patients. Consider sunscreen use due to photosensitivity risk. Not for oral administration.
Take ACTICLATE CAP only if directed by a healthcare professional after a poisoning or overdose.,This medication is not for regular use; it is a one-time emergency treatment.,Avoid taking this with food or drinks; take on an empty stomach for best absorption of toxins.,You may experience black stools or vomiting; this is normal.,Seek immediate medical attention if you have trouble swallowing, severe vomiting, or signs of bowel obstruction.
Apply foam to affected areas of face once daily, avoiding eyes and mouth.,Wash hands after application.,May cause temporary yellowing of skin or fingernails; not harmful.,Use sunscreen and protective clothing to prevent sunburn.,Do not swallow or apply to large skin areas.,Inform doctor if pregnant, breastfeeding, or planning pregnancy.,Avoid using other topical products on treated areas unless directed by doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTICLATE CAP vs AMZEEQ, answered by our medical review team.
ACTICLATE CAP is a Tetracycline Antibiotic that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.. AMZEEQ is a Tetracycline Antibiotic that works by Topical antibiotic and anti-inflammatory: inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and reduces pro-inflammatory cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTICLATE CAP and AMZEEQ depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTICLATE CAP is: 350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.. The standard adult dose of AMZEEQ is: Apply a thin layer to affected areas twice daily (morning and evening). Topical, 1.5% w/w.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTICLATE CAP and AMZEEQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTICLATE CAP is classified as Category C. First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known t. AMZEEQ is classified as Category C. Limited human data; animal studies show no teratogenic effects at systemic exposures up to 1.7 times the MRHD. No known fetal risk; avoid first trimester due to theoretical risk fr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.